Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $4.80K | $2.53M | $9.36M | $6.16M |
| Revenue growth | — | — | 52627.4% | 269.7% | -34.2% |
| Gross profit | — | $4.34K | — | — | — |
| Gross margin | — | 90.3% | — | — | — |
| Operating income | -$2.21M | -$4.01M | -$7.97M | -$8.95M | -$10.6M |
| Operating margin | — | -83511.5% | -314.8% | -95.6% | -171.6% |
| Net income | -$6.33M | -$8.15M | -$7.94M | -$9.04M | -$14.9M |
| Net margin | — | -169771.2% | -313.4% | -96.6% | -242.0% |
| EPS (diluted) | — | -$1.81 | -$0.91 | -$22.50 | -$8.66 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$2.05M | -$4.07M | -$6.04M | -$7.26M | -$9.33M |
| Capital expenditures | — | $220K | $22.9K | $79.1K | $60.6K |
| Free cash flow | — | -$4.29M | -$6.06M | -$7.34M | -$9.39M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.36M | $11.4M | $2.82M | $1.11M | $6.45M |
| Total assets | $1.45M | $12.2M | $8.22M | $6.51M | $11.0M |
| Total liabilities | $13.2M | $1.14M | $3.37M | $3.91M | $3.68M |
| Shareholders' equity | -$15.8M | $11.0M | $4.86M | $2.60M | $7.28M |
| Retained earnings | -$28.5M | -$36.7M | -$44.6M | -$53.6M | -$68.6M |
| Shares (wtd avg diluted) | 2.68M | 4.50M | 8.75M | 404K | 1.72M |
Every figure is extracted from bioAffinity Technologies, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.